Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia

C. D. Bloomfield, L. M. Secker-Walker, A. I. Goldman, H. Van Den Berghe, A. de la Chapelle, T. Ruutu, G. Alimena, O. M. Garson, H. M. Golomb, J. D. Rowley, Y. Kaneko, J. Whang-Peng, E. Prigogina, P. Philip, A. A. Sandberg, S. D. Lawler, F. Mitelman

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

To evaluate the importance of pretreatment karyotype in predicting long-term outcome in acute lymphoblastic leukemia (ALL), we performed a follow-up study of the 329 patients from the Third International Workshop on Chromosomes in Leukemia. Living patients have now been followed a minimum of 6 years. Patients were divided into ten groups according to pretreatment karyotype: no abnormalities, one of the following structural abnormalities [the Philadelphia chromosome, rearrangements involving 8q24, t(4;11), 14q+, 6q-] or, in the remaining cases, modal number (<46, 46, 47-50, >50). As previously reported for achievement and duration of complete remission, and overall survival, disease-free survival differed significantly (p < 0.001) among chromosome groups for both adults and children. Among children, karyotype was an independent prognostic factor for predicting disease-free survival. Because of the long follow-up, we now have been able to utilize statistical models to estimate the percentage of patients cured, according to karyotype alone and combined with other risk factors. Adults with the highest likelihood of cure (21-33%) were those patients with FAB-L1, a leukocyte count of 50,000/μl or less, and one of the following chromosome groups: greater than 50, 47-50, 6q-, or normal. In children these same characteristics were associated with the highest percentage of cure (58-71% cured). In addition, we identified several groups of children with less than 15% chance of cure who clearly need to be treated as high-risk patients at diagnosis. Future studies of patients who have received risk-adapted therapy based on these chromosome data are needed to determine if more intensive treatment will improve the outlook of patients with cytogenetically unfavorable types of ALL.

Original languageEnglish
Pages (from-to)171-185
Number of pages15
JournalCancer Genetics and Cytogenetics
Volume40
Issue number2
DOIs
Publication statusPublished - Jul 15 1989
Externally publishedYes

Fingerprint

Karyotype
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Chromosomes
Disease-Free Survival
Philadelphia Chromosome
Statistical Models
Leukocyte Count
Leukemia
Education
Survival
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Bloomfield, C. D., Secker-Walker, L. M., Goldman, A. I., Van Den Berghe, H., de la Chapelle, A., Ruutu, T., ... Mitelman, F. (1989). Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 40(2), 171-185. https://doi.org/10.1016/0165-4608(89)90023-X

Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. / Bloomfield, C. D.; Secker-Walker, L. M.; Goldman, A. I.; Van Den Berghe, H.; de la Chapelle, A.; Ruutu, T.; Alimena, G.; Garson, O. M.; Golomb, H. M.; Rowley, J. D.; Kaneko, Y.; Whang-Peng, J.; Prigogina, E.; Philip, P.; Sandberg, A. A.; Lawler, S. D.; Mitelman, F.

In: Cancer Genetics and Cytogenetics, Vol. 40, No. 2, 15.07.1989, p. 171-185.

Research output: Contribution to journalArticle

Bloomfield, CD, Secker-Walker, LM, Goldman, AI, Van Den Berghe, H, de la Chapelle, A, Ruutu, T, Alimena, G, Garson, OM, Golomb, HM, Rowley, JD, Kaneko, Y, Whang-Peng, J, Prigogina, E, Philip, P, Sandberg, AA, Lawler, SD & Mitelman, F 1989, 'Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia', Cancer Genetics and Cytogenetics, vol. 40, no. 2, pp. 171-185. https://doi.org/10.1016/0165-4608(89)90023-X
Bloomfield CD, Secker-Walker LM, Goldman AI, Van Den Berghe H, de la Chapelle A, Ruutu T et al. Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics. 1989 Jul 15;40(2):171-185. https://doi.org/10.1016/0165-4608(89)90023-X
Bloomfield, C. D. ; Secker-Walker, L. M. ; Goldman, A. I. ; Van Den Berghe, H. ; de la Chapelle, A. ; Ruutu, T. ; Alimena, G. ; Garson, O. M. ; Golomb, H. M. ; Rowley, J. D. ; Kaneko, Y. ; Whang-Peng, J. ; Prigogina, E. ; Philip, P. ; Sandberg, A. A. ; Lawler, S. D. ; Mitelman, F. / Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. In: Cancer Genetics and Cytogenetics. 1989 ; Vol. 40, No. 2. pp. 171-185.
@article{6328605b3e5047f9b575bc99f3e58d84,
title = "Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia",
abstract = "To evaluate the importance of pretreatment karyotype in predicting long-term outcome in acute lymphoblastic leukemia (ALL), we performed a follow-up study of the 329 patients from the Third International Workshop on Chromosomes in Leukemia. Living patients have now been followed a minimum of 6 years. Patients were divided into ten groups according to pretreatment karyotype: no abnormalities, one of the following structural abnormalities [the Philadelphia chromosome, rearrangements involving 8q24, t(4;11), 14q+, 6q-] or, in the remaining cases, modal number (<46, 46, 47-50, >50). As previously reported for achievement and duration of complete remission, and overall survival, disease-free survival differed significantly (p < 0.001) among chromosome groups for both adults and children. Among children, karyotype was an independent prognostic factor for predicting disease-free survival. Because of the long follow-up, we now have been able to utilize statistical models to estimate the percentage of patients cured, according to karyotype alone and combined with other risk factors. Adults with the highest likelihood of cure (21-33{\%}) were those patients with FAB-L1, a leukocyte count of 50,000/μl or less, and one of the following chromosome groups: greater than 50, 47-50, 6q-, or normal. In children these same characteristics were associated with the highest percentage of cure (58-71{\%} cured). In addition, we identified several groups of children with less than 15{\%} chance of cure who clearly need to be treated as high-risk patients at diagnosis. Future studies of patients who have received risk-adapted therapy based on these chromosome data are needed to determine if more intensive treatment will improve the outlook of patients with cytogenetically unfavorable types of ALL.",
author = "Bloomfield, {C. D.} and Secker-Walker, {L. M.} and Goldman, {A. I.} and {Van Den Berghe}, H. and {de la Chapelle}, A. and T. Ruutu and G. Alimena and Garson, {O. M.} and Golomb, {H. M.} and Rowley, {J. D.} and Y. Kaneko and J. Whang-Peng and E. Prigogina and P. Philip and Sandberg, {A. A.} and Lawler, {S. D.} and F. Mitelman",
year = "1989",
month = "7",
day = "15",
doi = "10.1016/0165-4608(89)90023-X",
language = "English",
volume = "40",
pages = "171--185",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia

AU - Bloomfield, C. D.

AU - Secker-Walker, L. M.

AU - Goldman, A. I.

AU - Van Den Berghe, H.

AU - de la Chapelle, A.

AU - Ruutu, T.

AU - Alimena, G.

AU - Garson, O. M.

AU - Golomb, H. M.

AU - Rowley, J. D.

AU - Kaneko, Y.

AU - Whang-Peng, J.

AU - Prigogina, E.

AU - Philip, P.

AU - Sandberg, A. A.

AU - Lawler, S. D.

AU - Mitelman, F.

PY - 1989/7/15

Y1 - 1989/7/15

N2 - To evaluate the importance of pretreatment karyotype in predicting long-term outcome in acute lymphoblastic leukemia (ALL), we performed a follow-up study of the 329 patients from the Third International Workshop on Chromosomes in Leukemia. Living patients have now been followed a minimum of 6 years. Patients were divided into ten groups according to pretreatment karyotype: no abnormalities, one of the following structural abnormalities [the Philadelphia chromosome, rearrangements involving 8q24, t(4;11), 14q+, 6q-] or, in the remaining cases, modal number (<46, 46, 47-50, >50). As previously reported for achievement and duration of complete remission, and overall survival, disease-free survival differed significantly (p < 0.001) among chromosome groups for both adults and children. Among children, karyotype was an independent prognostic factor for predicting disease-free survival. Because of the long follow-up, we now have been able to utilize statistical models to estimate the percentage of patients cured, according to karyotype alone and combined with other risk factors. Adults with the highest likelihood of cure (21-33%) were those patients with FAB-L1, a leukocyte count of 50,000/μl or less, and one of the following chromosome groups: greater than 50, 47-50, 6q-, or normal. In children these same characteristics were associated with the highest percentage of cure (58-71% cured). In addition, we identified several groups of children with less than 15% chance of cure who clearly need to be treated as high-risk patients at diagnosis. Future studies of patients who have received risk-adapted therapy based on these chromosome data are needed to determine if more intensive treatment will improve the outlook of patients with cytogenetically unfavorable types of ALL.

AB - To evaluate the importance of pretreatment karyotype in predicting long-term outcome in acute lymphoblastic leukemia (ALL), we performed a follow-up study of the 329 patients from the Third International Workshop on Chromosomes in Leukemia. Living patients have now been followed a minimum of 6 years. Patients were divided into ten groups according to pretreatment karyotype: no abnormalities, one of the following structural abnormalities [the Philadelphia chromosome, rearrangements involving 8q24, t(4;11), 14q+, 6q-] or, in the remaining cases, modal number (<46, 46, 47-50, >50). As previously reported for achievement and duration of complete remission, and overall survival, disease-free survival differed significantly (p < 0.001) among chromosome groups for both adults and children. Among children, karyotype was an independent prognostic factor for predicting disease-free survival. Because of the long follow-up, we now have been able to utilize statistical models to estimate the percentage of patients cured, according to karyotype alone and combined with other risk factors. Adults with the highest likelihood of cure (21-33%) were those patients with FAB-L1, a leukocyte count of 50,000/μl or less, and one of the following chromosome groups: greater than 50, 47-50, 6q-, or normal. In children these same characteristics were associated with the highest percentage of cure (58-71% cured). In addition, we identified several groups of children with less than 15% chance of cure who clearly need to be treated as high-risk patients at diagnosis. Future studies of patients who have received risk-adapted therapy based on these chromosome data are needed to determine if more intensive treatment will improve the outlook of patients with cytogenetically unfavorable types of ALL.

UR - http://www.scopus.com/inward/record.url?scp=0024317523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024317523&partnerID=8YFLogxK

U2 - 10.1016/0165-4608(89)90023-X

DO - 10.1016/0165-4608(89)90023-X

M3 - Article

C2 - 2766242

AN - SCOPUS:0024317523

VL - 40

SP - 171

EP - 185

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 2

ER -